Immuron Limited - Product Pipeline Review - 2012

Report Overview

Table of Contents

958.44

Select License Type

£958.44	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,916.88	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£2,875.33	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.44	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Company Profile
Country	Global
Published	31 October 2012
Number of Pages	56
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	Global Markets Direct
File Format	PDF

Immuron Limited – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Immuron Limited - Product Pipeline Review - 2012" provides data on the Immuron Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from our proprietary databases, Immuron Limited's corporate website, SEC filings, investor presentations and featured press releases, both from Immuron Limited and industry-specific third party sources, put together by our team.

Scope

- Immuron Limited - Brief Immuron Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immuron Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immuron Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immuron Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immuron Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immuron Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immuron Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immuron Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immuron Limited and identify potential opportunities in those areas.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£958.44	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,916.88	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£2,875.33	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£958.44	Add to Wishlist
Change Currency	GBP EURO USD

Table of Contents
List of Tables
List of Figures
Immuron Limited Snapshot
Immuron Limited Overview
Key Information
Key Facts
Immuron Limited – Research and Development Overview
Key Therapeutic Areas
Immuron Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Immuron Limited – Pipeline Products Glance
Immuron Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Immuron Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Immuron Limited – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Immuron Limited – Drug Profiles
IMM-124E
Product Description
Mechanism of Action
R&D Progress
IMM-160
Product Description
Mechanism of Action
R&D Progress
IMM-243
Product Description
Mechanism of Action
R&D Progress
IMM-252
Product Description
Mechanism of Action
R&D Progress
IMM-255
Product Description
Mechanism of Action
R&D Progress
IMM-272
Product Description
Mechanism of Action
R&D Progress
IMM-308
Product Description
Mechanism of Action
R&D Progress
Immuron Limited – Pipeline Analysis
Immuron Limited – Pipeline Products by Therapeutic Class
Immuron Limited – Pipeline Products by Route of Administration
Immuron Limited – Recent Pipeline Updates
Immuron Limited – Locations And Subsidiaries
Head Office
Immuron Limited, Recent Developments
Immuron Limited- Press Release
Jun 04, 2012: Paladin Labs And Immuron Announce Health Canada Acceptance Of Travelan's Application For Review
Jan 10, 2012: FDA Clears Investigational New Drug Application & Phase IIb Trial For Immuron's Nash/Fatty Liver Therapeutic
Financial Deals Landscape
Immuron Limited, Deals Summary
Immuron Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Immuron Enters Into Co-Development Agreement With Monash University
Nycomed Enters Into Co-Development Agreement With Immuron
Immuron Enters Into Distribution Agreement With Alaven
Hadasit Forms Joint Venture With Anadis
Licensing Agreements
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan
Nycomed Expands Its Licensing Agreement With Immuron
Nycomed Enters Into Licensing Agreement With Immuron
Hadasit Enters Into Licensing Agreement With Immuron
ImmuCell Enters Into Cross-License Agreement With Immuron
Anadis Enters Into Licensing Agreement With ImmuCell
Equity Offering
Immuron Completes Private Placement Of Shares For $0.5 Million
Immuron Announces Rights Issue Of Common Shares For $4.6 Million
Immuron Completes Public Offering Of $0.64 Million
Immuron Completes Private Placement Of $0.69 Million
Immuron Completes Private Placement Of $0.09 Million
Immuron Completes Private Placement Of $0.25 Million
Anadis Completes Private Placement Of $0.77 Million
Anadis Completes Private Placement Of $0.6 Million
Anadis Completes Private Placement Of $1.3 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Immuron Limited, Key Information
Immuron Limited, Key Facts
Immuron Limited – Pipeline by Indication, 2012
Immuron Limited – Pipeline by Stage of Development, 2012
Immuron Limited – Monotherapy Products in Pipeline, 2012
Immuron Limited – Phase III, 2012
Immuron Limited – Phase II, 2012
Immuron Limited – Phase I, 2012
Immuron Limited – Pre-Clinical, 2012
Immuron Limited – Discovery, 2012
Immuron Limited – Pipeline By Therapeutic Class, 2012
Immuron Limited – Pipeline By Route of Administration, 2012
Immuron Limited – Recent Pipeline Updates, 2012
Immuron Limited, Deals Summary
Immuron Enters Into Co-Development Agreement With Monash University
Nycomed Enters Into Co-Development Agreement With Immuron
Immuron Enters Into Distribution Agreement With Alaven
Hadasit Forms Joint Venture With Anadis
Paladin Labs Enters Into Licensing Agreement With Immuron For Travelan
Nycomed Expands Its Licensing Agreement With Immuron
Nycomed Enters Into Licensing Agreement With Immuron
Hadasit Enters Into Licensing Agreement With Immuron
ImmuCell Enters Into Cross-License Agreement With Immuron
Anadis Enters Into Licensing Agreement With ImmuCell
Immuron Completes Private Placement Of Shares For $0.5 Million
Immuron Announces Rights Issue Of Common Shares For $4.6 Million
Immuron Completes Public Offering Of $0.64 Million
Immuron Completes Private Placement Of $0.69 Million
Immuron Completes Private Placement Of $0.09 Million
Immuron Completes Private Placement Of $0.25 Million
Anadis Completes Private Placement Of $0.77 Million
Anadis Completes Private Placement Of $0.6 Million
Anadis Completes Private Placement Of $1.3 Million

List of Figures

Immuron Limited – Pipeline by Indication, 2012
Immuron Limited – Pipeline by Stage of Development, 2012
Immuron Limited – Monotherapy Products in Pipeline, 2012
Immuron Limited – Pipeline By Therapeutic Class, 2012 24

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Immuron Limited - Product Pipeline Review - 2012

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Immuron Limited - Product Pipeline Review - 2012

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel